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were 30 cases with DVT and 18 with PAO. It was not stated whether some patients were excluded for any reason from the initial study sample.
Study design
This was a retrospective cohort study that was conducted at a single centre (details not provided). The length of followup was not reported. The duration of therapy depended on the results of the follow-up angiograms. No patients appear to have been lost to the follow-up assessment. No details of the outcome evaluation were provided.
Analysis of effectiveness
It appears that all the patients included in the initial study sample have been accounted for in the analysis of effectiveness. The health outcomes used were: thrombolytic success, defined as complete or partial lysis with PAO (improvement of the International Society for Cardiovascular Surgery/Society for Vascular Surgery scale by one or more classifications) or DVT (resolution of the acute pain and oedema of the extremity after intervention); and rate of major or minor complications.
Major complications were defined as death, intracranial haemorrhage, or bleeding requiring transfusion or surgery, or an increase in length of hospital stay. Minor complications were defined as adverse events requiring only conservative therapy, such as small access site haematomas.
Infusion-related outcomes, such as the hourly-infused dose, total drug dose, and infusion time, were also assessed. A multivariate regression analysis was conducted to identify potential predictors of thrombolytic complications. The study groups were comparable at baseline in terms of their demographics and disease characteristics.
Effectiveness results
The complete and partial thrombolytic success rate for the whole sample was 88.9% with t-PA (87.5% for DVT and 90.5% for PAO) and 85.4% with URK (83.4% for DVT and 88.9% for PAO). These differences did not reach statistical significance.
Similarly, no statistically significant differences were observed in terms of major and minor complications. In particular, both groups had one major complication (1 patient receiving t-PA had spontaneous lower gastrointestinal bleeding and 1 patient receiving URK had a large access site haematoma).
There were no deaths, intracranial haemorrhages, need for intensive care unit monitoring, or surgical interventions in either group.
Four patients (8.9%) treated with t-PA and 5 (10.4%) with URK had minor bleeding events.
The infusion time was 24.6 (+/-11) hours for t-PA and 33.3 (+/-13.3) hours for URK, (p=0.0009), for the whole sample.
Similar results were obtained in the sub-groups of DVT and PAO patients.
The hourly-infused dose was 0.86 (+/-0.50) mg/hour with t-PA and 13.5 (+/-5.6) 4 U/hour with URK.
The total drug dose was 21.1 (+/-15.1) mg with t-PA and 4.485 (+/-2.394) million U with URK.
The multivariate regression analysis showed that none of the baseline factors was significantly associated with the rate of complications. a long time, while t-PA was used as an alternative treatment because of the possible risks associated with URK. You should decide whether they are valid comparators in your own setting.
Validity of estimate of measure of effectiveness
The analysis of effectiveness was based on a retrospective review of patients' charts. Since the outcomes were estimated in two different timeframes, some factors other than the study interventions could have affected the study results, despite the baseline comparability of the two groups of patients. Some time-related bias could also have been introduced. The authors controlled the impact of potential confounding factors on some outcome measures and, subsequently, it was found that none of them was a predictor of complications.
No justification for the sample size was given. In addition, it was unclear whether the study sample was appropriate for the study question, although the study groups appear to have been comparable in terms of demographics and disease characteristics. Limited information on the follow-up was provided. Further, the evidence came from a single centre. The method of selecting the patients was not described, thus it could not be assessed whether the study sample was representative of the patient population. These issues tend to limit the internal validity of the analysis.
Validity of estimate of measure of benefit
No summary benefit measure was used in the analysis because a cost-minimisation analysis was conducted.
Validity of estimate of costs
The perspective of the study was not explicitly reported, but only the drug costs were considered. The impact of the interventions on other health care resources was not investigated. This was manly due to the equal efficacy of the two treatments. Therefore, it was implicitly assumed that services pertaining to, for example, the treatment of adverse events, were comparable. The source of the data was reported, as were the dates when resource use was collected. The unit costs were not presented. The cost estimates were specific to the study setting and no sensitivity analyses were conducted. Statistical tests were performed when the costs were compared. The years during which the costs were estimated were reported.
